Cargando…
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
Background. Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741360/ https://www.ncbi.nlm.nih.gov/pubmed/26620652 http://dx.doi.org/10.1093/cid/civ963 |
_version_ | 1782413978286161920 |
---|---|
author | Hofstra, L. Marije Sauvageot, Nicolas Albert, Jan Alexiev, Ivailo Garcia, Federico Struck, Daniel Van de Vijver, David A. M. C. Åsjö, Birgitta Beshkov, Danail Coughlan, Suzie Descamps, Diane Griskevicius, Algirdas Hamouda, Osamah Horban, Andrzej Van Kasteren, Marjo Kolupajeva, Tatjana Kostrikis, Leondios G. Liitsola, Kirsi Linka, Marek Mor, Orna Nielsen, Claus Otelea, Dan Paraskevis, Dimitrios Paredes, Roger Poljak, Mario Puchhammer-Stöckl, Elisabeth Sönnerborg, Anders Staneková, Danica Stanojevic, Maja Van Laethem, Kristel Zazzi, Maurizio Zidovec Lepej, Snjezana Boucher, Charles A. B. Schmit, Jean-Claude Wensing, Annemarie M. J. |
author_facet | Hofstra, L. Marije Sauvageot, Nicolas Albert, Jan Alexiev, Ivailo Garcia, Federico Struck, Daniel Van de Vijver, David A. M. C. Åsjö, Birgitta Beshkov, Danail Coughlan, Suzie Descamps, Diane Griskevicius, Algirdas Hamouda, Osamah Horban, Andrzej Van Kasteren, Marjo Kolupajeva, Tatjana Kostrikis, Leondios G. Liitsola, Kirsi Linka, Marek Mor, Orna Nielsen, Claus Otelea, Dan Paraskevis, Dimitrios Paredes, Roger Poljak, Mario Puchhammer-Stöckl, Elisabeth Sönnerborg, Anders Staneková, Danica Stanojevic, Maja Van Laethem, Kristel Zazzi, Maurizio Zidovec Lepej, Snjezana Boucher, Charles A. B. Schmit, Jean-Claude Wensing, Annemarie M. J. |
author_sort | Hofstra, L. Marije |
collection | PubMed |
description | Background. Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. Methods. Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)–infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. Results. The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%–9.5%) in 2008–2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. Conclusions. Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected. |
format | Online Article Text |
id | pubmed-4741360 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-47413602016-02-05 Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe Hofstra, L. Marije Sauvageot, Nicolas Albert, Jan Alexiev, Ivailo Garcia, Federico Struck, Daniel Van de Vijver, David A. M. C. Åsjö, Birgitta Beshkov, Danail Coughlan, Suzie Descamps, Diane Griskevicius, Algirdas Hamouda, Osamah Horban, Andrzej Van Kasteren, Marjo Kolupajeva, Tatjana Kostrikis, Leondios G. Liitsola, Kirsi Linka, Marek Mor, Orna Nielsen, Claus Otelea, Dan Paraskevis, Dimitrios Paredes, Roger Poljak, Mario Puchhammer-Stöckl, Elisabeth Sönnerborg, Anders Staneková, Danica Stanojevic, Maja Van Laethem, Kristel Zazzi, Maurizio Zidovec Lepej, Snjezana Boucher, Charles A. B. Schmit, Jean-Claude Wensing, Annemarie M. J. Clin Infect Dis HIV/AIDS Background. Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. Methods. Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)–infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. Results. The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%–9.5%) in 2008–2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. Conclusions. Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected. Oxford University Press 2016-03-01 2015-11-29 /pmc/articles/PMC4741360/ /pubmed/26620652 http://dx.doi.org/10.1093/cid/civ963 Text en © The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, contact journals.permissions@oup.com. |
spellingShingle | HIV/AIDS Hofstra, L. Marije Sauvageot, Nicolas Albert, Jan Alexiev, Ivailo Garcia, Federico Struck, Daniel Van de Vijver, David A. M. C. Åsjö, Birgitta Beshkov, Danail Coughlan, Suzie Descamps, Diane Griskevicius, Algirdas Hamouda, Osamah Horban, Andrzej Van Kasteren, Marjo Kolupajeva, Tatjana Kostrikis, Leondios G. Liitsola, Kirsi Linka, Marek Mor, Orna Nielsen, Claus Otelea, Dan Paraskevis, Dimitrios Paredes, Roger Poljak, Mario Puchhammer-Stöckl, Elisabeth Sönnerborg, Anders Staneková, Danica Stanojevic, Maja Van Laethem, Kristel Zazzi, Maurizio Zidovec Lepej, Snjezana Boucher, Charles A. B. Schmit, Jean-Claude Wensing, Annemarie M. J. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe |
title | Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe |
title_full | Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe |
title_fullStr | Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe |
title_full_unstemmed | Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe |
title_short | Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe |
title_sort | transmission of hiv drug resistance and the predicted effect on current first-line regimens in europe |
topic | HIV/AIDS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741360/ https://www.ncbi.nlm.nih.gov/pubmed/26620652 http://dx.doi.org/10.1093/cid/civ963 |
work_keys_str_mv | AT hofstralmarije transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT sauvageotnicolas transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT albertjan transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT alexievivailo transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT garciafederico transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT struckdaniel transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT vandevijverdavidamc transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT asjobirgitta transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT beshkovdanail transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT coughlansuzie transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT descampsdiane transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT griskeviciusalgirdas transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT hamoudaosamah transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT horbanandrzej transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT vankasterenmarjo transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT kolupajevatatjana transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT kostrikisleondiosg transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT liitsolakirsi transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT linkamarek transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT mororna transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT nielsenclaus transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT oteleadan transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT paraskevisdimitrios transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT paredesroger transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT poljakmario transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT puchhammerstocklelisabeth transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT sonnerborganders transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT stanekovadanica transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT stanojevicmaja transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT vanlaethemkristel transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT zazzimaurizio transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT zidoveclepejsnjezana transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT bouchercharlesab transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT schmitjeanclaude transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope AT wensingannemariemj transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope |